H.R. 2369 118th Congress
VALID Act of 2023
- Health
- Sponsor: Rep. Bucshon, Larry [R-IN-8]
- Congress.gov ↗
Latest action, Apr 7, 2023: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
3 cosponsors
Sponsored by Rep. Bucshon, Larry [R-IN-8] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 1 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED)
CAPITOL COUNSEL LLC
8 reports
ARUP LABORATORIES, INC.
VAN SCOYOC ASSOCIATES
8 reports
ASSOCIATION FOR MOLECULAR PATHOLOGY
IPOLICY SOLUTIONS
8 reports
HOOPER,LUNDY& BOOKMAN, PC (OBO ROCHE DIAGNOSTICS)
GOVERNMENT COUNSEL, LLC
8 reports
LABORATORY CORPORATION OF AMERICA HOLDINGS
KELLEY DRYE & WARREN LLP
8 reports
8 reports
THE UNIVERSITY OF UTAH
VAN SCOYOC ASSOCIATES
8 reports
8 reports
UNIVERSITY OF NEW MEXICO
VAN SCOYOC ASSOCIATES
8 reports
7 reports
7 reports
COALITION FOR INNOVATIVE LABORATORY TESTING, INC.
COMPASS GOVERNMENT RELATIONS PARTNERS, LLC
7 reports
All 25 of 49 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ADVANCED MEDICAL TECHNOLOGY ASSN | 8 | $6.7M | Q1 2023 | Q3 2024 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | CAPITOL COUNSEL LLC | 8 | $380K | Q1 2023 | Q3 2024 | yes |
| ARUP LABORATORIES, INC. | VAN SCOYOC ASSOCIATES | 8 | $240K | Q1 2023 | Q3 2024 | yes |
| ASSOCIATION FOR MOLECULAR PATHOLOGY | IPOLICY SOLUTIONS | 8 | $492K | Q1 2023 | Q3 2024 | yes |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 8 | $5.4M | Q1 2023 | Q3 2024 | yes | |
| HOOPER,LUNDY& BOOKMAN, PC (OBO ROCHE DIAGNOSTICS) | GOVERNMENT COUNSEL, LLC | 8 | $100K | Q1 2023 | Q3 2024 | yes |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | KELLEY DRYE & WARREN LLP | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | 8 | $3.7M | Q1 2023 | Q3 2024 | yes | |
| QUEST DIAGNOSTICS INCORPORATED | 8 | $3.9M | Q1 2023 | Q3 2024 | yes | |
| THE UNIVERSITY OF UTAH | VAN SCOYOC ASSOCIATES | 8 | $420K | Q1 2023 | Q3 2024 | yes |
| THERMO FISHER SCIENTIFIC INC | 8 | $4.0M | Q1 2023 | Q3 2024 | yes | |
| UNIVERSITY OF NEW MEXICO | VAN SCOYOC ASSOCIATES | 8 | $280K | Q1 2023 | Q3 2024 | yes |
| ABBOTT LABORATORIES | 7 | $7.2M | Q1 2023 | Q3 2024 | yes | |
| CARDINAL HEALTH INC | 7 | $2.8M | Q4 2023 | Q3 2024 | yes | |
| COALITION FOR INNOVATIVE LABORATORY TESTING, INC. | COMPASS GOVERNMENT RELATIONS PARTNERS, LLC | 7 | $9,000 | Q4 2023 | Q3 2024 | yes |
| FOUNDATION MEDICINE, INC. | 7 | $670K | Q4 2023 | Q3 2024 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 7 | $397K | Q4 2023 | Q3 2024 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 7 | $2.1M | Q4 2023 | Q3 2024 | yes | |
| NMDP | VAN SCOYOC ASSOCIATES | 7 | $780K | Q4 2023 | Q3 2024 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | CROSSROADS STRATEGIES, LLC | 6 | $300K | Q4 2023 | Q3 2024 | yes |
| AMERICAN MEDICAL TECHNOLOGISTS | MICHAEL N. MCCARTY LAW OFFICE PLLC | 6 | $60K | Q4 2023 | Q3 2024 | yes |
| BECTON DICKINSON AND COMPANY | 6 | $3.2M | Q1 2023 | Q2 2024 | yes | |
| INVITAE INC. | IPOLICY SOLUTIONS | 6 | $475K | Q1 2023 | Q2 2024 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | DLA PIPER LLP (US) | 5 | $240K | Q4 2023 | Q3 2024 | yes |
| AMERICAN CLINICAL LABORATORY ASSN | 5 | $2.6M | Q1 2023 | Q3 2024 | yes |